argenx (ARGX) vs Exelixis (EXEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Exelixis (EXEL) has outperformed argenx (ARGX) over the past year, gaining 47.5% versus a gain of 16.4%. Over five years, ARGX leads with a +216.1% price change compared with +167.8% for EXEL. argenx is the larger company by market cap ($51.89 billion vs $14.47 billion), about 3.6 times the size.
On valuation, Exelixis trades at a lower forward P/E (13.8x vs 23.8x for argenx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | EXEL |
|---|---|---|
| Share price | $825.08 | $58.39 |
| Market cap | $51.89B | $14.47B |
| 1-day change | -11.13% | -0.09% |
| YTD return | +10.40% | +33.33% |
| 1-year return | +16.44% | +47.46% |
| 5-year return | +216.08% | +167.83% |
| P/E ratio (TTM) | 31.44 | 18.42 |
| Forward P/E | 23.76 | 13.77 |
| EPS (TTM) | $26.24 | $3.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.32B |
| Revenue growth (YoY) | — | +6.98% |
| Net income (latest FY) | $1.29B | $782.57M |
| Gross margin | — | 96.39% |
| Operating margin | — | 37.59% |
| Net margin | — | 33.73% |
| 52-week high | $1,072.75 | $61.14 |
| 52-week low | $661.85 | $33.76 |
| Distance from 52-week high | -23.09% | -4.50% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +43.05% | -6.61% |
| Average volume | 283.40K | 2.34M |
| Shares outstanding | 62.89M | 247.78M |
| Employees | 1,863 | 1,077 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 3.6 times larger than Exelixis by market value ($51.89B vs $14.47B).
- EXEL has outperformed ARGX by 31.0 percentage points over the past year.
- argenx trades at a higher earnings multiple (31.4x vs 18.4x trailing P/E).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
ARGX vs EXEL FAQ
Which is bigger, argenx or Exelixis?
argenx (ARGX) is larger, with a market capitalization of $51.89B compared with $14.47B for Exelixis (EXEL).
Which stock has performed better over the past year, ARGX or EXEL?
EXEL returned +47.46% over the past 12 months, compared with +16.44% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or EXEL?
EXEL has the lower trailing P/E at 18.4, versus 31.4 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are argenx and Exelixis in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.